SKYRIZI (risankizumab-rzaa) and COSENTYX head-to-head study: SKYRIZI advantagesignificant

AbbVie recently released the latest Phase IIIb head-to-head study data, which showed that the skin removal rate of psoriasis patients in the SKYRIZI group was better than that of the COSENTYX (secukinumab) group"We have seen the incredible positive impact of SKYRIZI (risankizumab-rzaa) on psoriasis patients," said DrRichard BWarren, lead researcher at AbbVieAt week 16, 74% of THE PATIENTS TREATED WITH SKYRIZI reached PASI 90, compared with 66% of patients treated with COSENTYXThe proportion of patients treated with SKYRIZI reaching PASI 90 at 52 weeks was 87% compared to 57% of patients treated with COSENTYX (p .001)At 52 weeks, 66% of patients with psoriasis treated with SKYRIZI had their skin completely removed - the psoriasis area reached a 100% removal rate (PASI 100), while only 40% of patients receiving COSENTYX reached PASI 100 (p 0.001)The data will be presented at the American Academy of Dermatology (AAD) virtual meeting in 2020